Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Renal Cell Carcinoma

PF-05082566 (4-1BB agonist mAb) for Advanced Cancer or B-Cell Lymphoma (UW10051)
A Phase 1 Study Of PF-05082566 As A Single Agent In Patients With Advanced Cancer, And In Combination With Rituximab In Patients With Non-Hodgkin's Lymphoma (NHL)
Status Conditions Phase Study ID
Recruiting Non-Hodgkin's Lymphoma (NHL) Phase I NCT01307267
Summary

Phase 1 dose escalation study of PF-05082566, a 4-1BB agonist monoclonal antibody (mAb). Safety and dose-finding study of PF-05082566 single agent in patients with solid tumors or b-cell lymphomas, and in combination with rituximab in patients with CD20 positive Non-Hodgkin's Lymphoma (NHL).


Investigator
Ajay K. Gopal, MD
Location    
SCCA Phase 1 Program Office 206-288-7551 Refer Patient
Eligibility Criteria (must meet the following to participate in this study)

 

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

Adequate bone marrow, renal, liver and cardiac function

Exclusion Criteria:

Autoimmune disorders, CNS malignancies

Last Updated
October 02, 2012
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.